BBO-10203 + FOLFOX + bevacizumab

This is a combination regimen consisting of **BBO-10203** (a first-in-class small molecule inhibitor that disrupts the RAS-PI3Kα protein-protein interaction signaling pathway), **FOLFOX** (a chemotherapy regimen combining folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin used primarily for colorectal cancer), and **bevacizumab** (a humanized monoclonal antibody targeting and inhibiting vascular endothelial growth factor A (VEGF-A), used to suppress tumor angiogenesis). BBO-10203 is experimental and in early-phase clinical trials for advanced solid tumors, showing promise in cancers with RAS or PI3K pathway mutations. FOLFOX is a standard chemotherapeutic backbone, and bevacizumab is routinely combined with chemotherapy for metastatic colorectal cancer and various other tumors[1][2][3][6][7].